Aimmune Therapeutics (AIMT) – Press Releases
-
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
-
European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
-
Nestlé completes acquisition of Aimmune Therapeutics
-
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
-
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
-
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
-
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
-
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
-
AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm
-
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
-
Nestlé to acquire Aimmune Therapeutics
-
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
-
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
-
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
-
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
-
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
-
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
-
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
-
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
-
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
-
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
-
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
-
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
-
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
-
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
-
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
-
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
-
Aimmune Therapeutics to Present at Upcoming Investor Conferences
-
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
-
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
-
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
-
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
-
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
-
Aimmune to Participate in Three Upcoming Investor Conferences
-
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments
-
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge
-
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
-
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
-
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
-
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference
-
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
-
Aimmune to Present at the Cantor Global Healthcare Conference
-
FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
-
Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
-
Aimmune to Participate in Three Investor Conferences in September
-
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
Back to AIMT Stock Lookup
